- Home
- WINT vs SXTC Comparison
WINT vs SXTC Comparison
Compare WINT & SXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- SXTC
- Stock Information
- Founded
- WINT 1992
- SXTC 2005
- Country
- WINT United States
- SXTC China
- Employees
- WINT N/A
- SXTC N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- SXTC Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- SXTC Health Care
- Exchange
- WINT Nasdaq
- SXTC Nasdaq
- Market Cap
- WINT 1.5M
- SXTC N/A
- IPO Year
- WINT 1995
- SXTC 2019
- Fundamental
- Price
- WINT $1.39
- SXTC $2.57
- Analyst Decision
- WINT Hold
- SXTC
- Analyst Count
- WINT 1
- SXTC 0
- Target Price
- WINT $350.00
- SXTC N/A
- AVG Volume (30 Days)
- WINT 7.7M
- SXTC 1.6M
- Earning Date
- WINT 04-15-2025
- SXTC 01-01-0001
- Dividend Yield
- WINT N/A
- SXTC N/A
- EPS Growth
- WINT N/A
- SXTC N/A
- EPS
- WINT N/A
- SXTC N/A
- Revenue
- WINT N/A
- SXTC $1,928,497.00
- Revenue This Year
- WINT N/A
- SXTC N/A
- Revenue Next Year
- WINT N/A
- SXTC N/A
- P/E Ratio
- WINT N/A
- SXTC N/A
- Revenue Growth
- WINT N/A
- SXTC N/A
- 52 Week Low
- WINT $1.10
- SXTC $2.40
- 52 Week High
- WINT $737.50
- SXTC $26.96
- Technical
- Relative Strength Index (RSI)
- WINT 30.13
- SXTC 48.21
- Support Level
- WINT $1.10
- SXTC $2.66
- Resistance Level
- WINT $2.17
- SXTC $3.09
- Average True Range (ATR)
- WINT 0.35
- SXTC 0.22
- MACD
- WINT 0.20
- SXTC -0.13
- Stochastic Oscillator
- WINT 12.18
- SXTC 23.53
Stock Price Comparison Chart: WINT vs SXTC
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.